Background: CD19-directed chimeric antigen receptor T-cell (CAR-19) therapies are promising new options in relapsed or refractory diffuse large B-cell lymphoma (DLBCL), but over half of patients still progress. Recent whole-genome sequencing data published by our lab revealed that deletion of RHOA (3p21.31) is strongly associated with poor response (p = 0.0013). In newly diagnosed DLBCL, 20% of patients harbor a RHOA deletion and another 5% have loss-of-function mutations.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile